Milestone Pharmaceuticals Inc.
MIST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001408443
No open-market purchases or sales by Milestone Pharmaceuticals Inc. insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $66.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Milestone Pharmaceuticals Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 47 | 1 | 43 | −3 |
| Shares | 24.6M | 100 | 11.8M | −12.7M (−51.8%) |
| Value | $57.9M | $236 | $9.46M | −$48.5M (−83.7%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Milestone Pharmaceuticals Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Propel Bio Management, LLC | 1,451,557 | $1.16M | 1.35% |
| Simplify Asset Management Inc. | 850,000 | $680.1K | 0.03% |
| LPL Financial LLC | 111,540 | $89.2K | 0.00% |
| Walleye Capital LLC | 91,920 | $73.5K | 0.00% |
| Two Sigma Advisers, LP | 76,000 | $60.8K | 0.00% |
| Bank of America Corp | 39,396 | $31.5K | 0.00% |
| Raymond James Financial Inc | 33,235 | $26.6K | 0.00% |
| Safeguard Investment Advisory Group, LLC | 25,044 | $20.0K | 0.01% |
| Scientech Research LLC | 22,918 | $18.3K | 0.00% |
| Journey Strategic Wealth LLC | 15,000 | $12.0K | 0.00% |
| Integrated Wealth Concepts LLC | 10,000 | $8.00K | 0.00% |
| Royal Bank of Canada | 10,000 | $8.00K | 0.00% |
| US Bancorp | 3,200 | $2.56K | 0.00% |
| SBI Securities Co., Ltd. | 4 | $3 | 0.00% |
Sold out (17)
Institutions that held Milestone Pharmaceuticals Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| BlackRock, Inc. | 4,050,686 | $9.56M |
| OrbiMed Advisors LLC | 2,000,000 | $4.72M |
| Nantahala Capital Management, LLC | 1,445,264 | $3.41M |
| Goldman Sachs Group Inc | 942,407 | $2.22M |
| Citadel Advisors LLC | 608,202 | $1.44M |
| Ikarian Capital, LLC | 466,030 | $1.10M |
| Boxer Capital Management, LLC | 309,007 | $729.3K |
| Virtu Financial LLC | 71,955 | $170.0K |
| Envestnet Asset Management Inc | 63,742 | $150.4K |
| Squarepoint Ops LLC | 56,751 | $133.9K |
| Atria Investments LLC | 38,666 | $91.3K |
| Cubist Systematic Strategies, LLC | 30,938 | $73.0K |
| Boothbay Fund Management, LLC | 30,790 | $72.7K |
| Cetera Investment Advisers | 24,731 | $58.4K |
| Two Sigma Securities, LLC | 16,957 | $40.0K |
| Advisor Group Holdings, Inc. | 6,934 | $16.4K |
| Barclays PLC | 100 | $236 |
Not filed for Q1 2025 yet (1)
Institutions that held Milestone Pharmaceuticals Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Oliver Lagore Vanvalin Investment Group | 100 | $236 |